Thursday Amarin Corporation Plc (AMRN) $AMRN opened at 1.60 hitting the high price of 1.61 and a day low of 1.53 with a total volume of 1,794,812. AMRN had a previous close of 1.58 and has been seeing an average volume of 1,441,165.
Overall Average: 80% Sell
Recent stock forum discussions about AMRN http://investorshangout.com/search?q=AMRN&...mp;yt0=Go!
Amarin to Report First Quarter 2014 Results and Host Conference Call on May 9, 2014
GlobeNewswire - Mon May 05, 8:41AM CDT
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2014 financial results and provide an operational update on Friday, May 9, at 8:00 a.m. ET. The conference call will follow the anticipated release of the company's first quarter 2014 financial results earlier that day. (full story)
Amarin Announces Presentation of New MARINE and ANCHOR Post-Hoc Analyses at National Lipid Association Annual Scientific Sessions Showing Vascepa(R) Significantly Reduced Apolipoprotein C-III Levels
GlobeNewswire - Fri May 02, 7:01AM CDT
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the presentation at the National Lipid Association Annual Scientific Sessions, of new post-hoc analyses of the MARINE and ANCHOR studies that showed the use of Vascepa (icosapent ethyl) capsules significantly reduced apolipoprotein C-III (ApoC-III) levels. ApoC-III is a small protein that resides on various lipoproteins, and is an important regulator of lipoprotein and triglyceride (TG) metabolism. This research is being presented today by Christie M. Ballantyne, M.D. from Baylor College of Medicine as part of a peer-reviewed poster session at the National Lipid Association Annual Scientific Sessions in Orlando, Florida. (full story)
Technical Roundup on Health Care Stocks -- Research on Amarin, United Therapeutics, Hologic, and NxStage Medical
PR Newswire - Fri Apr 25, 1:10PM CDT
On Thursday, April 24, 2014, the NASDAQ Composite ended at 4,148.34, up 0.52%, the Dow Jones Industrial Average finished the day flat at 16,501.65, and the S&P 500 closed at 1,878.61, up 0.17%. The gains were narrow based as four out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.80, down 0.20%, while the index has advanced 0.39% in the last one month. Investor-Edge has initiated coverage on the following equities: Amarin Corp. PLC (NASDAQ: AMRN), United Therapeutics Corp. (NASDAQ: UTHR), Hologic Inc. (NASDAQ: HOLX) and NxStage Medical Inc. (NASDAQ: NXTM). Free technical research on AMRN, UTHR, HOLX and NXTM can be downloaded upon signing up at: (full story)
The Supreme Court Will Decide the Fate of a Blockbuster
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Apr 14, 5:30PM CDT
Recently, Teva Pharmaceuticals lost a patent lawsuit over its multiple sclerosis drug Copaxone, which makes up a crucial 40% of the company's income. However, the U.S. Supreme Court has announced that it will hear Teva's appeal of this Appeals... (full story)
Amarin Corp. and Kowa Pharmaceuticals to Begin Joint Vascepa Promotion in May
ACCESSWIRE - Fri Apr 11, 11:25AM CDT
Amarin Corp. PLC (NASDAQ:AMRN) stock volume was tepid Apr. 10, with just 1,595,690 shares, a third of its three-month average volume of 4,405,235 shares. (full story)
More Trouble Looming for Amarin Corporation?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 09, 1:30PM CDT
Amarin Corp. can't seem to catch a break these days. Almost immediately after inking a co-promotional deal for the company's lone commercial product, Vascepa, with Kowa Pharmaceuticals America, Teva Pharmaceuticals announced yesterday they are... (full story)
Partner Signed! Is Amarin's Turnaround Beginning?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sun Apr 06, 11:12AM CDT
Amarin has announced news long awaited by investors -- a partnership with a big pharma. Although the pharma itself is not a household name, Japan's Kowa Pharmaceuticals will essentially triple the sales force for Vascepa. Sales of the... (full story)
Can This Drive Growth for Amarin Corporation plc?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Apr 01, 1:30PM CDT
Small-cap biopharmaceutical Amarin has made it clear that the company is not giving up on Vascepa without a fight, several of them actually. In addition to challenging the FDA's decisions to rescind a Special Protocol Assessment (SPA) on the... (full story)
Amarin and Kowa Pharmaceuticals America, Inc. Announce U.S. Co-Promotion Agreement for Vascepa(R) (icosapent ethyl) Capsules
GlobeNewswire - Mon Mar 31, 3:37PM CDT
Amarin Corporation plc (Nasdaq:AMRN) and Kowa Pharmaceuticals America, Inc., two biopharmaceutical companies focused on the development and commercialization of therapeutics to improve cardiovascular health, today announced an agreement to co-promote Amarin's flagship product, Vascepa (icosapent ethyl) capsules, in the United States. Vascepa is approved for use in the United States as an adjunct to diet to reduce triglyceride levels in adult patients with severe (greater-than or equal to 500 mg/dL) hypertriglyceridemia. In bringing together two companies focused on the primary care and cardiovascular health communities, the agreement is designed to benefit a greater number of patients. (full story)
Biotech Equities Technical Study -- Research on Prana Biotechnology, Amarin, United Therapeutic, and OPKO Health
PR Newswire - Fri Mar 28, 11:19AM CDT
On Thursday, March 27, 2014, the NASDAQ Composite ended at 4,151.23, down 0.54%, the Dow Jones Industrial Average edged 0.03% lower to 16,264.23, and the S&P 500 closed at 1,849.04, down 0.19%. The losses were broad based with seven out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index finished the day at 671.20, down 0.13%, and the index has fallen by 2.20% in last one month. Investor-Edge has initiated coverage on the following equities: Prana Biotechnology Ltd (NASDAQ: PRAN), Amarin Corp. PLC (NASDAQ: AMRN), United Therapeutics Corp. (NASDAQ: UTHR) and OPKO Health Inc. (NYSE: OPK). Free technical research on PRAN, AMRN, UTHR and OPK can be downloaded upon signing up at: (full story)
Amarin Corporation plc. Analyst Report: Special Situation \ Turnaround Opportunity in Biopharmaceuticals - Targeting large existing cardiovascular health market by BrokerBank Securities, Inc.
PR Newswire - Fri Mar 28, 6:00AM CDT
Amarin Corporation plc (NASDAQ: AMRN), an established biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health is in the process of attempting a turnaround to return to a growth trajectory. The Company's lead product, Vascepa (icosapent ethyl) capsules, is approved by the U.S. FDA for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. (full story)
3 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Mar 28, 5:00AM CDT
Keep these under-$10 biotech stocks on your radar. (full story)
Better Chance of Making a Comeback: Amarin plc or VIVUS, Inc.?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 21, 1:30PM CDT
I am a strong advocate of investing in so-called "comeback stories." My belief is underscored by the notable comebacks of Best Buy and Netflix in recent times. Within a few short months , Best Buy gained more than 200% and Netflix did even... (full story)
Biotech Stock Mailbag: Amarin, Cytrx, Sangamo and 'Story Stocks'
at The Street - Fri Mar 21, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies. (full story)
5 Stocks Under $10 Set to Soar
at The Street - Thu Mar 13, 12:30PM CDT
These under-$10 stocks look ready to trade higher from current levels. (full story)
3 Stocks Under $10 Triggering Breakouts
at The Street - Wed Mar 12, 5:00AM CDT
These under-$10 stocks are within range of triggering breakout trades. (full story)
If You Can't Make Your Drug a Blockbuster, Sue Your Competitor
Brian Orelli, The Motley Fool - Motley Fool - Tue Mar 04, 4:34PM CST
Amarin 's lawyers sure are keeping busy. The company is appealing the Food and Drug Administration's decision to rescind the Special Protocol Assessment, or SPA, for its fish oil pill Vascepa. The SPA would allow the biotech to gain expanded... (full story)
Can Amarin Corporation PLC Stop Burning Cash?
Brian Orelli, The Motley Fool - Motley Fool - Fri Feb 28, 1:16PM CST
A 20% quarter-over-quarter growth may sound like solid growth, but not when it only gets you to $10.1 million in net sales. It's hard to be impressed by the launch of Amarin 's fish oil Vascepa. To put it in perspective, the biotech had $22 million... (full story)
Amarin Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Update on Operations
GlobeNewswire - Thu Feb 27, 3:14PM CST
Amarin Corporation plc (Nasdaq:AMRN), a late stage biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter and year ended December 31, 2013, and provided an update on company operations. (full story)
Two Years Less Exclusivity Is the Least of Amarin's Issues
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 25, 8:30AM CST
The Food and Drug Administration usually takes about a month to make a decision about how long a drug will have exclusivity. Unless you're Amarin . Then it takes about 19 months. And the answer isn't exactly what investors were hoping for. On... (full story)
Overall Average: 80% Sell
Recent stock forum discussions about AMRN http://investorshangout.com/search?q=AMRN&...mp;yt0=Go!
Amarin to Report First Quarter 2014 Results and Host Conference Call on May 9, 2014
GlobeNewswire - Mon May 05, 8:41AM CDT
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2014 financial results and provide an operational update on Friday, May 9, at 8:00 a.m. ET. The conference call will follow the anticipated release of the company's first quarter 2014 financial results earlier that day. (full story)
Amarin Announces Presentation of New MARINE and ANCHOR Post-Hoc Analyses at National Lipid Association Annual Scientific Sessions Showing Vascepa(R) Significantly Reduced Apolipoprotein C-III Levels
GlobeNewswire - Fri May 02, 7:01AM CDT
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the presentation at the National Lipid Association Annual Scientific Sessions, of new post-hoc analyses of the MARINE and ANCHOR studies that showed the use of Vascepa (icosapent ethyl) capsules significantly reduced apolipoprotein C-III (ApoC-III) levels. ApoC-III is a small protein that resides on various lipoproteins, and is an important regulator of lipoprotein and triglyceride (TG) metabolism. This research is being presented today by Christie M. Ballantyne, M.D. from Baylor College of Medicine as part of a peer-reviewed poster session at the National Lipid Association Annual Scientific Sessions in Orlando, Florida. (full story)
Technical Roundup on Health Care Stocks -- Research on Amarin, United Therapeutics, Hologic, and NxStage Medical
PR Newswire - Fri Apr 25, 1:10PM CDT
On Thursday, April 24, 2014, the NASDAQ Composite ended at 4,148.34, up 0.52%, the Dow Jones Industrial Average finished the day flat at 16,501.65, and the S&P 500 closed at 1,878.61, up 0.17%. The gains were narrow based as four out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.80, down 0.20%, while the index has advanced 0.39% in the last one month. Investor-Edge has initiated coverage on the following equities: Amarin Corp. PLC (NASDAQ: AMRN), United Therapeutics Corp. (NASDAQ: UTHR), Hologic Inc. (NASDAQ: HOLX) and NxStage Medical Inc. (NASDAQ: NXTM). Free technical research on AMRN, UTHR, HOLX and NXTM can be downloaded upon signing up at: (full story)
The Supreme Court Will Decide the Fate of a Blockbuster
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Apr 14, 5:30PM CDT
Recently, Teva Pharmaceuticals lost a patent lawsuit over its multiple sclerosis drug Copaxone, which makes up a crucial 40% of the company's income. However, the U.S. Supreme Court has announced that it will hear Teva's appeal of this Appeals... (full story)
Amarin Corp. and Kowa Pharmaceuticals to Begin Joint Vascepa Promotion in May
ACCESSWIRE - Fri Apr 11, 11:25AM CDT
Amarin Corp. PLC (NASDAQ:AMRN) stock volume was tepid Apr. 10, with just 1,595,690 shares, a third of its three-month average volume of 4,405,235 shares. (full story)
More Trouble Looming for Amarin Corporation?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 09, 1:30PM CDT
Amarin Corp. can't seem to catch a break these days. Almost immediately after inking a co-promotional deal for the company's lone commercial product, Vascepa, with Kowa Pharmaceuticals America, Teva Pharmaceuticals announced yesterday they are... (full story)
Partner Signed! Is Amarin's Turnaround Beginning?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sun Apr 06, 11:12AM CDT
Amarin has announced news long awaited by investors -- a partnership with a big pharma. Although the pharma itself is not a household name, Japan's Kowa Pharmaceuticals will essentially triple the sales force for Vascepa. Sales of the... (full story)
Can This Drive Growth for Amarin Corporation plc?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Apr 01, 1:30PM CDT
Small-cap biopharmaceutical Amarin has made it clear that the company is not giving up on Vascepa without a fight, several of them actually. In addition to challenging the FDA's decisions to rescind a Special Protocol Assessment (SPA) on the... (full story)
Amarin and Kowa Pharmaceuticals America, Inc. Announce U.S. Co-Promotion Agreement for Vascepa(R) (icosapent ethyl) Capsules
GlobeNewswire - Mon Mar 31, 3:37PM CDT
Amarin Corporation plc (Nasdaq:AMRN) and Kowa Pharmaceuticals America, Inc., two biopharmaceutical companies focused on the development and commercialization of therapeutics to improve cardiovascular health, today announced an agreement to co-promote Amarin's flagship product, Vascepa (icosapent ethyl) capsules, in the United States. Vascepa is approved for use in the United States as an adjunct to diet to reduce triglyceride levels in adult patients with severe (greater-than or equal to 500 mg/dL) hypertriglyceridemia. In bringing together two companies focused on the primary care and cardiovascular health communities, the agreement is designed to benefit a greater number of patients. (full story)
Biotech Equities Technical Study -- Research on Prana Biotechnology, Amarin, United Therapeutic, and OPKO Health
PR Newswire - Fri Mar 28, 11:19AM CDT
On Thursday, March 27, 2014, the NASDAQ Composite ended at 4,151.23, down 0.54%, the Dow Jones Industrial Average edged 0.03% lower to 16,264.23, and the S&P 500 closed at 1,849.04, down 0.19%. The losses were broad based with seven out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index finished the day at 671.20, down 0.13%, and the index has fallen by 2.20% in last one month. Investor-Edge has initiated coverage on the following equities: Prana Biotechnology Ltd (NASDAQ: PRAN), Amarin Corp. PLC (NASDAQ: AMRN), United Therapeutics Corp. (NASDAQ: UTHR) and OPKO Health Inc. (NYSE: OPK). Free technical research on PRAN, AMRN, UTHR and OPK can be downloaded upon signing up at: (full story)
Amarin Corporation plc. Analyst Report: Special Situation \ Turnaround Opportunity in Biopharmaceuticals - Targeting large existing cardiovascular health market by BrokerBank Securities, Inc.
PR Newswire - Fri Mar 28, 6:00AM CDT
Amarin Corporation plc (NASDAQ: AMRN), an established biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health is in the process of attempting a turnaround to return to a growth trajectory. The Company's lead product, Vascepa (icosapent ethyl) capsules, is approved by the U.S. FDA for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. (full story)
3 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Mar 28, 5:00AM CDT
Keep these under-$10 biotech stocks on your radar. (full story)
Better Chance of Making a Comeback: Amarin plc or VIVUS, Inc.?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 21, 1:30PM CDT
I am a strong advocate of investing in so-called "comeback stories." My belief is underscored by the notable comebacks of Best Buy and Netflix in recent times. Within a few short months , Best Buy gained more than 200% and Netflix did even... (full story)
Biotech Stock Mailbag: Amarin, Cytrx, Sangamo and 'Story Stocks'
at The Street - Fri Mar 21, 6:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies. (full story)
5 Stocks Under $10 Set to Soar
at The Street - Thu Mar 13, 12:30PM CDT
These under-$10 stocks look ready to trade higher from current levels. (full story)
3 Stocks Under $10 Triggering Breakouts
at The Street - Wed Mar 12, 5:00AM CDT
These under-$10 stocks are within range of triggering breakout trades. (full story)
If You Can't Make Your Drug a Blockbuster, Sue Your Competitor
Brian Orelli, The Motley Fool - Motley Fool - Tue Mar 04, 4:34PM CST
Amarin 's lawyers sure are keeping busy. The company is appealing the Food and Drug Administration's decision to rescind the Special Protocol Assessment, or SPA, for its fish oil pill Vascepa. The SPA would allow the biotech to gain expanded... (full story)
Can Amarin Corporation PLC Stop Burning Cash?
Brian Orelli, The Motley Fool - Motley Fool - Fri Feb 28, 1:16PM CST
A 20% quarter-over-quarter growth may sound like solid growth, but not when it only gets you to $10.1 million in net sales. It's hard to be impressed by the launch of Amarin 's fish oil Vascepa. To put it in perspective, the biotech had $22 million... (full story)
Amarin Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Update on Operations
GlobeNewswire - Thu Feb 27, 3:14PM CST
Amarin Corporation plc (Nasdaq:AMRN), a late stage biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter and year ended December 31, 2013, and provided an update on company operations. (full story)
Two Years Less Exclusivity Is the Least of Amarin's Issues
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 25, 8:30AM CST
The Food and Drug Administration usually takes about a month to make a decision about how long a drug will have exclusivity. Unless you're Amarin . Then it takes about 19 months. And the answer isn't exactly what investors were hoping for. On... (full story)
